Our CSF-based approach provides higher pathophysiological specificity by directly reflecting CNS processes, yet the heterogeneous pathological substrate underlying FTD variants (including TDP-43, tau, and other proteinopathies) limits the utility of tau-based markers alone. This evidence concerns the gene MAPT and proteostasis deficiencies.